Noxopharm (ASX:NOX) is an Australian-based clinical-stage drug development company with offices in Sydney and New York. Veyonda is the first pipeline drug candidate which is being trialed as a treatment for a broad range of solid tumor cancers and for septic shock. Later generation drug candidates for large markets of unmet medical need such as brain and pancreatic cancer are being developed in an active R&D program. The fully-owned subsidiary, Pharmorage Pty Ltd, was created in 2020 and has a focus on inflammation and autoimmune diseases.Likes and shares are not endorsements